Kyverna Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 60.37 million compared to USD 28.89 million a year ago. Basic loss per share from continuing operations was USD 89.61 compared to USD 63.43 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13 USD | +4.59% | -15.69% | 0.00% |
May. 14 | Kyverna Therapeutics Q1 Loss Narrows | MT |
Apr. 25 | Nasdaq's revenue beats on strong demand for fintech products | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 560M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+44.98% | 40.65B | |
-10.87% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- KYTX Stock
- News Kyverna Therapeutics, Inc.
- Kyverna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023